Market Closed -
London S.E.
09:05:08 21/06/2024 pm IST
|
5-day change
|
1st Jan Change
|
10.9
GBX
|
-6.44%
|
|
-24.04%
|
-56.75%
|
Fiscal Period: August |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
69.59
|
59.1
|
93.03
|
129.2
|
61.73
|
17.19
|
8.077
|
-
|
Enterprise Value (EV)
1 |
56.64
|
59.1
|
95.7
|
129
|
61.73
|
17.19
|
12.48
|
10.68
|
P/E ratio
|
-9.9
x
|
-
|
-11
x
|
-26.1
x
|
-5.39
x
|
4.1
x
|
-3.03
x
|
14.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
290
x
|
346
x
|
183
x
|
34.7
x
|
16.3
x
|
-
|
2.86
x
|
1.17
x
|
EV / Revenue
|
236
x
|
346
x
|
188
x
|
34.7
x
|
16.3
x
|
-
|
4.42
x
|
1.54
x
|
EV / EBITDA
|
-9.14
x
|
-
|
-10.9
x
|
-29.3
x
|
-
|
-
|
-5.68
x
|
7.08
x
|
EV / FCF
|
-
|
-
|
-10.5
x
|
-25.9
x
|
-
|
-
|
-3.47
x
|
6.28
x
|
FCF Yield
|
-
|
-
|
-9.55%
|
-3.85%
|
-
|
-
|
-28.9%
|
15.9%
|
Price to Book
|
4.63
x
|
-
|
-473
x
|
24.7
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
61,588
|
63,212
|
63,503
|
69,084
|
69,437
|
74,104
|
74,104
|
-
|
Reference price
2 |
1.130
|
0.9350
|
1.465
|
1.870
|
0.8890
|
0.2320
|
0.1090
|
0.1090
|
Announcement Date
|
31/10/18
|
31/10/19
|
30/10/20
|
02/11/21
|
27/02/23
|
29/02/24
|
-
|
-
|
Fiscal Period: August |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
0.24
|
0.171
|
0.509
|
3.722
|
3.788
|
-
|
2.822
|
6.915
|
EBITDA
1 |
-6.194
|
-
|
-8.768
|
-4.405
|
-
|
-
|
-2.195
|
1.508
|
EBIT
1 |
-6.374
|
-
|
-9.268
|
-5.145
|
-
|
-
|
-2.027
|
1.046
|
Operating Margin
|
-2,655.83%
|
-
|
-1,820.83%
|
-138.23%
|
-
|
-
|
-71.83%
|
15.13%
|
Earnings before Tax (EBT)
1 |
-6.342
|
-
|
-9.783
|
-5.696
|
-
|
-
|
-2.676
|
0.552
|
Net income
1 |
-6.342
|
-
|
-8.459
|
-4.628
|
-
|
4.104
|
-2.669
|
0.552
|
Net margin
|
-2,642.5%
|
-
|
-1,661.89%
|
-124.34%
|
-
|
-
|
-94.58%
|
7.98%
|
EPS
2 |
-0.1141
|
-
|
-0.1336
|
-0.0717
|
-0.1649
|
0.0566
|
-0.0360
|
0.007400
|
Free Cash Flow
1 |
-
|
-
|
-9.139
|
-4.973
|
-
|
-
|
-3.6
|
1.7
|
FCF margin
|
-
|
-
|
-1,795.48%
|
-133.61%
|
-
|
-
|
-127.57%
|
24.58%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
112.73%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
307.97%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
31/10/18
|
31/10/19
|
30/10/20
|
02/11/21
|
27/02/23
|
29/02/24
|
-
|
-
|
Fiscal Period: August |
2024 S1
|
2024 S2
|
---|
Net sales
1 |
-
|
1.636
|
EBITDA
1 |
-
|
-0.838
|
EBIT
1 |
-
|
-1.269
|
Operating Margin
|
-
|
-77.57%
|
Earnings before Tax (EBT)
1 |
-
|
-1.57
|
Net income
1 |
-1.099
|
-1.57
|
Net margin
|
-
|
-95.97%
|
EPS
2 |
-0.000150
|
-0.0212
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
21/05/24
|
-
|
Fiscal Period: August |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
2.67
|
-
|
-
|
-
|
4.4
|
2.6
|
Net Cash position
1 |
13
|
-
|
-
|
0.14
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.3044
x
|
-
|
-
|
-
|
-2.005
x
|
1.724
x
|
Free Cash Flow
1 |
-
|
-
|
-9.14
|
-4.97
|
-
|
-
|
-3.6
|
1.7
|
ROE (net income / shareholders' equity)
|
-68.3%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
0.2400
|
-
|
-0
|
0.0800
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-0.1100
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.03
|
-
|
0.24
|
0.45
|
-
|
-
|
0.07
|
0.08
|
Capex / Sales
|
12.92%
|
-
|
46.37%
|
11.98%
|
-
|
-
|
2.48%
|
1.08%
|
Announcement Date
|
31/10/18
|
31/10/19
|
30/10/20
|
02/11/21
|
27/02/23
|
29/02/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -56.75% | 1.02Cr | | +15.72% | 7.75TCr | | +13.65% | 894.1Cr | | -24.30% | 428.16Cr | | +12.79% | 417.67Cr | | +31.45% | 411.22Cr | | +10.97% | 222.69Cr | | -30.57% | 206.28Cr | | +8.99% | 197.09Cr | | -45.76% | 169.37Cr |
Specialty & Advanced Pharmaceuticals
|